Novel pharmacological agents in clinical development for solid tumours

Expert Opinion on Investigational Drugs

Volumn 10, Issue 12, 2001, Pages 2059-2088

  Dy, G K ^a   Haluska, P ^a   Adjei, A A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Antisense oligonucleotide; Cyclin dependent kinase; Extracellular matrix; Farnesyltransferase inhibitors; Heat shock protein; Monoclonal antibodies; Proteasome; Protein kinase C inhibitors; Ras; Receptor tyrosine kinase inhibitors; Signal transduction; Ubiquitin

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 7 HYDROXYSTAUROSPORINE; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BORTEZOMIB; BRYO; BRYOSTATIN 1; CGS 27023A; CL 1033; DNA; ENDOSTATIN; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; ISIS 2503; ISIS 3521; KW 2401; LONAFARNIB; MIDOSTAURIN; PHOSPHOTRANSFERASE INHIBITOR; PRINOMASTAT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SEMAXANIB; SORAFENIB; TANOMASTAT; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TARGETING; DRUG TOXICITY; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTENSION; LIVER TOXICITY; MOLECULAR BIOLOGY; MYALGIA; NEUROTOXICITY; NEUTROPENIA; RASH; REGULATORY MECHANISM; REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 0035218360     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.12.2059     Document Type: Review

References (208)

1. Autocrine growth factors and cancer
2. Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer
3. Antitumour activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer
4. Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour APC5
5. Processing and proliferative effects of human progastrin in transgenic mice
6. Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin
7. Clinical outcome of advanced colorectal cancer patients treated with the anti-gastrin immunogen, Gastrimmune
8. Epidermal growth factor-related peptides and their receptors in human malignancies
9. Neutralising antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumour cells in vitro and in vivo: Angiogenic for signal transduction therapy of solid tumours
10. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
11. Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
12. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation
13. Continued response following treatment with IMC-C225, an EGFr moAb, combined with RT in advanced head and neck malignancies
14. Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer treatment
15. Signal transduction pathway targets for anticancer drug discovery
16. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumour types: Evidence of activity and good tolerability
17. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-Tki), shows evidence of good tolerability and activity: Final results from a phase I study
18. The epidermal growth factor receptor and its inhibition in cancer therapy
19. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
20. Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
21. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux
22. Radiosensitisation of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor
23. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase
24. Blocking oncogenic ras signalling for cancer therapy
25. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and independent growth of human tumour cell lines
26. Farnesyltransferase inhibitors
27. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R-115777 in advanced cancer
28. Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R-115777 on a 21-day dosing schedule
29. A Phase I trial of the farnesyl transferase inhibitor SCH-66336: Evidence for biological and clinical activity
30. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumours
31. Synergy of the protein farnesyltransferase inhibitor SCH-66336 and cisplatin in human cancer cell lines
32. Activity of a farnesyl transferase inhibitor (SCH 66336) against a broad range of tumours taken directly from patients
33. Phase I Clinical, Pharmacokinetic and pharmacodynamic study of the Raf kinase inhibitor BAY 43-9006 in patients with locally advanced or metastatic cancer
34. Blockade of the MAP kinase pathway suppresses growth of colon tumours in vivo
35. Phase I and pharmacological study of CCI-779, a cell cycle inhibitor
36. CCI-779, a rapamycin analogue with antitumour activity: A Phase I study utilising a weekly schedule
37. Phase 1 and pharmacokinetic trial of ISIS-2503, a 20-mer antisense oligonucleotide against H-ras, ny 14-day continuous infusion (CIV) in patients with advanced cancer
38. A Phase I trial of ISIS-2503, an antisense inhibitor of H-ras, administered by a 24-Hour (hr) weekly infusion to patients (pts) with advanced cancer
39. Multicentre Phase II trial of an antisense inhibitor of H-ras (ISIS-2503) in advanced non-small cell lung cancer (NSCLC)
40. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS-5132 (CGP69846A)
41. A Phase I trial of c-raf kinase antisense oligonucleotide ISIS-5132 administered as a continuous intravenous infusion in patients with advanced cancer
42. Phase I trial of ISIS-5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
43. Disruption of the MAP kinase signalling pathway using antisense oligonucleotide inhibitors targeted to ras and raf kinase
44. Preclinical and clinical development of cyclin-dependent kinase modulators
45. Cyclin-dependent kinase and Protein Kinase C inhibitors: A novel class of antineoplastic agents in clinical development
46. Protein kinase C involvement in apoptosis
47. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway
48. Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line
49. Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors
50. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes
51. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
52. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
53. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study
54. A phase II trial of flavopiridol in patients with stage IV non-small cell lung cancer
55. Phase II study of the cyclin-dependent kinase inhibitor Flavopiridol administered to patients with advanced gastric carcinoma
56. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
57. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
58. Phase I trial of sequential paclitaxel and the cyclin dependent kinase inhibitor flavopiridol
59. 2 checkpoint function in cancer cells with disrupted p53
60. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G (2) checkpoint abrogation
61. The radiosensitising agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1
62. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
63. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function
64. 2-checkpoint inhibitor
65. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner
66. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukaemia cells
67. Phase I trial of 72-Hour continuous infusion UCN-01 in patients with refractory neoplasms
68. Differential p53-dependent mechanism of radiosensitisation in vitro and in vivo by the Protein Kinase C-specific inhibitor PKC412
69. Phase I and pharmacokinetic study of PKC412, an inhibitor of Protein Kinase C
70. Inhibition of leukaemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin dependent kinase 2
71. The in vivo effect of bryostatin-1 on paclitaxel-induced tumour growth, mitotic entry, and blood flow
72. Effect of bryostatin-1 on Taxol-induced apoptosis and cytotoxicity in human leukaemia cells (U937)
73. Phase I evaluation of ISIS-3521, an antisense oligodeoxynucleotide to Protein Kinase C-alpha, in patients with advanced cancer
74. Phase I/II Trial of ISIS-3521, an antisense inhibitor of PKC-Alpha, with carboplatin and paclitaxel in non-small cell lung cancer
75. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity
76. Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients with advanced solid malignancies
77. Phase I pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumours
78. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression
79. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB
80. Tumour angiogenesis: Therapeutic implications
81. Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis
82. Current pathological methods for measuring intratumoural microvessel density within breast carcinoma and other solid tumours
83. Anticancer drug targets: Approaching angiogenesis
84. Thalidomide is an inhibitor of angiogenesis
85. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
86. Phase II trial of Thalidomide in renal cell carcinoma
87. A Phase II trial of weekly intravenous gemcitabine (G) with prolonged continuous infusion 5-fluorouracil (F) and oral thalidomide (T) in patients with metastatic renal cell cancer (mRCC)
88. Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance
89. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth
90. Human angiostatin inhibits murine haemangioendothelioma tumour growth in vivo
91. Angiostatin suppresses malignant glioma growth in vivo
92. Angiostatin induces and sustains dormancy of human primary tumours in mice
93. Recombinant human angiostatin (rhA): A phase I clinical trial assessing safety, pharmacokinetics (PK) and pharmacodynamics
94. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding
95. Phase I clinical trial of recombinant human endostatin (rHE) in patients with solid tumours: Pharmacokinetic (PK), safety and efficacy analysis using surrogate endpoints of tissue and radiologic response
96. A Phase I pharmacokinetic and pharmacodynamic trial of recombinant human endostatin
97. Vascular endothelial growth factor (VEGF) and its receptors
98. The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralising monoclonal antibodies
99. A Phase II trial of single agent rhumAb VEGF (recombinant humanised monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer
100. A randomised Phase II trial comparing rhumAb VEGF (recombinant humanised monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
101. Carboplatin (C)+ paclitaxel (T)+ rhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer
102. A randomised Phase II trial comparing rhumAb VEGF (recombinant humanised monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluoracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer
103. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
104. Phase Ib trial of intravenous recombinant humanised monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
105. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumour vascularisation, and growth of multiple tumour types
106. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
107. A Phase I and pharmacokinetic study of single oral administration of SU5416 in patients with advanced solid tumours
108. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies
109. Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies
110. SU6668 is a potent anti-angiogenic and antitumour agent that induces regression of established tumours
111. Angiozyme pharmacokinetic and safety results: A phase I/II study in patients with refractory solid tumours
112. Preclinical and clinical studies of MMP inhibitors in cancer
113. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomised trial
114. A randomised double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma
115. Broad antitumour and anti-angiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
116. Clinical studies with matrix metalloproteinase inhibitors
117. CGS 27023A, a potent and orally active matrix metalloprotease inhibitor with antitumour activity
118. Matrix metalloproteinase inhibitor (MMPI) CGS27023A inhibited extravasation of B16-F10 melanoma cells in the experimental metastatic model
119. A phase one pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor
120. A phase I study of the matrix metalloproteinase inhibitor MM1270 (previously termed CGS27023A) with 5FU and folinic acid
121. Promising new developments in cancer chemotherapy
122. Pharmacokinetic (PK) evaluation of BMS-275291, a matrix metalloproteinase (MMP) inhibitor, in cancer patients
123. A Phase I trial of BMS-275291: A novel, non-hydroxamate, sheddase-sparing matrix metalloproteinase inhibitor (MMPI) with no dose-limiting arthritis
124. Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells
125. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
126. Pharmacodynamic Studies of Col-3, a novel matrix metalloproteinase inhibitor, in patients with advanced cancer
127. AL: Æ-941 (Neovastat) induces the expression of angiostatin in experimental glioma
128. Phase I/II trials on the safety, tolerability and efficacy of Æ-941 (Neovastat) in patients with solid tumours
129. v integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
130. 3 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels
131. 3
132. 5 integrins; mature results of a Phase I and pharmacological study
133. A pilot trial demonstrates the safety of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), n combination with carboplatin (C) and paclitaxel (P) in previously advanced non-small cell lung cancer (NSCLC)
134. Final results of a phase I intermittent dose-escalation trial of ZD-1839('Iressa') in Japanese patients with various solid tumours
135. A Phase I Clinical and Biomarker Study of CI-1033, a Novel Pan-ErbB Tyrosine Kinase Inhibitor in Patients with Solid Tumours
136. A Phase 1 and pharmacokinetic study of CI-1033, a panErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid Tumours
137. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
138. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial
139. Phase I and pharmacologic study with the novel farnesyltransferase inhibitor (FTI) R-115777
140. A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of the farnesyl transferase inhibitor (FTI) R-115777 in Japanese patients with advanced non-haematological malignancies
141. Phase I trial of Irinotecan in combination with the farnesyl transferase inhibitor (FTI) R-115777
142. A Phase I, pharmacokinetic, and biologic correlative study of R-115777 and trastuzumab (Herceptin) in patients with advanced cancer
143. Phase I trial of 5-FU/LV in combination with the farnesyltransferase Inhibitor (FTI) R-115777
144. Phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R-115777 + Docetaxel: A promising combination in patients (PTS) with solid tumours
145. A Phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) R-115777 and Capecitabine in patients (PTS) with advanced solid malignancies
146. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumours
147. Induction therapy with SCH 66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck
148. Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH-66336 plus Gemcitabine in advanced cancers
149. Phase I study of farnesyl transferase inhibitor SCH-66336 with paclitaxel in solid tumours: Dose finding, pharmacokinetics, efficacy/safety
150. Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumours
151. A Phase I study of the farnesyltransferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in oatients (Pts) with advanced solid tumours: Clinical findings
152. Phase I clinical trial of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumours
153. Phase I study of farnesyl transferase inhibitor, BMS-214662 in solid tumours
154. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase (CDK) inhibitor Flavopiridol
155. A Phase I and pharmacologic study of UCN-01, a Protein Kinase C inhibitor
156. A Phase I/Pharmacologic study of UCN-01 (UCN) in combination with 5-Fluorouracil (F) in patients with advanced solid tumours
157. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion
158. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
159. Phase I trial of combination Bryostatin-1 and vincristine in B-cell malignancies
160. Phase I study of Bryostatin-1 and cisplatin in patients with advanced cancer
161. Phase I trial of weekly sequential Bryostatin-1 (Bryo), Cisplatin, and Paclitaxel in pts with advanced solid tumours
162. Phase I study of Bryostatin-1 and Cisplatin (CDDP)
163. Bryostatin 1 and Cisplatin: A phase I and pharmacodynamic study
164. A Phase I trial of ISIS-2503, an antisense inhibitor of H-ras in combination with Gemcitabine in patients with advanced cancer
165. A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumour malignancies
166. Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies
167. Phase I/II study of Carboplatin and Thalidomide in recurrent glioblastoma multiforme
168. Phase I/pharmacokinetic (PK) study of the metalloproteinase and angiogenesis inhibitor Bayer 12-9566 (BAY) in conjunction with f-fluorouracil/folinic acid (FU/FA)
169. A Phase I and pharmacokinetic study of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with paclitaxel and carboplatin
170. A phase I study of AG3340, a matrix metalloproteinase (MMP) inhibitor in patients having advanced cancer
171. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with Cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to containing chemotherapy
172. Phase II study of Anti-epidermal growth factor receptor (EGFr) antibody C225 alone in patients (pts) with metastatic renal cell carcinoma (RCC)
173. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with Gemcitabine in patients with advanced pancreatic cancer
174. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck
175. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma
176. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)
177. A Phase II study of the farnesyl transferase inhibitor R-115777 in patients with advanced breast cancer
178. Randomised Phase II study of SCH 66336 and Gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas
179. NCIC CTG IND.128: A Phase II study of a farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract failing prior chemotherapy
180. Phase II trial of Flavopiridol in metastatic colorectal cancer: Preliminary results
181. A Phase II Trial of weekly one hour paclitaxel followed by bryostatin-1 in patients with advanced oesophageal cancer: An active new drug combination
182. A Phase II trial of weekly Bryostatin-1 (Bryo-1) in metastatic renal cell carcinoma (RCC)
183. Phase II study of Bryostatin-1 in combination with Paclitaxel for advanced non-small cell lung cancer (NSCLC)
184. Phase II trial of Bryostatin-1 in patients with melanoma
185. NCIC CTG Randomised Phase II study of two schedules of Bryostatin 1 (NSC339555) in patients with advanced malignant melanoma (IND.1040
186. A phase II study of bryostatin 1 in metastatic malignant melanoma
187. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
188. A Phase II trial with antisense oligonucleotide ISIS-3521/Cgp 64128a in patients (pts) with metastatic breast cancer (MBC): ECOG Trial 3197
189. Phase II trial of ISIS-2503, an antisense inhibitor of H-ras, in patients (pts) with advanced pancreatic carcinoma (CA)
190. A phase II trial of ISIS-2503, an antisense inhibitor of H-ras, as first line therapy for advanced colorectal carcinoma
191. Phase II trial of Thalidomide in unresectable hepatocellular carcinoma (HCC)-a Cancer Therapeutics Research Group (CTRG) Study
192. Phase II trail of Thalomid (Thalidomide) for treatment of non-resectable hepatocellular carcinoma (HCC)
193. Phase II trial of Thalidomide in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCHN)
194. A Phase II evaluation of Thalidomide in patients with metastatic breast cancer
195. Irinotecan and Thalidomide in metastatic colorectal cancer: Preliminary results of a Phase II study
196. Phase II trial of Thalidomide in patients with metastatic renal cell carcinoma (RCC)
197. Phase II study of Thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin-2 (IL-2)-based therapy (Rx)
198. Phase II study of Thalidomide (T) in advanced refractory metastatic renal cell cancer (MRCC): A single institution experience
199. Phase II study of Thalidomide as an anti-angiogenic agent in the treatment of recurrent glioblastoma multiforme (GBM)
200. Thalidomide therapy for previously untreated, smoldering, and relapsed multiple myeloma (MM)
201. A Phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer
202. Phase II study of the matrix metalloprotease inhibitor prinomastat in patients with progressive breast cancer
203. A multicentre, randomised, double-blind, placebo (PB) controlled trial of marimastat (MT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS) following completion of conventional, first-line treatment
204. Randomised double-blind placebo-controlled trial of Marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: An NCIC-CTG and EORTC study
205. Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC)
206. Phase III study of the matrix metalloprotease (MMP) inhibitor Prinomastat in patients having advanced non-small cell lung cancer (NSCLC)
207. An International multicentre Phase III Study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/Paclitaxel + platinum containing chemotherapy (CT)
208. A comparison between Gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (PTS) with advanced pancreatic cancer